ProfileGDS5678 / 1425664_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 16% 17% 16% 13% 16% 16% 16% 28% 16% 16% 16% 16% 16% 16% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.4280516
GSM967853U87-EV human glioblastoma xenograft - Control 22.4027617
GSM967854U87-EV human glioblastoma xenograft - Control 32.397416
GSM967855U87-EV human glioblastoma xenograft - Control 42.2761613
GSM967856U87-EV human glioblastoma xenograft - Control 52.3458816
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.4472116
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.4164416
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.630228
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.3717716
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.3773716
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.3884316
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.3741116
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.3997716
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.3903616